IMATINIB-DRLA (Imatinib)
imatinib 400 mg capsule, 30 · ORAL · PBS code 11870R
STREAMLINEDWhat it costs
AU$160.05 PBS-determined price per 30 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2020-01-01.
- • Repeats: 2.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chronic Myeloid Leukaemia (CML)
Continuing treatment
Patient must have received initial PBS-subsidised treatment with this drug as a first-line therapy for this condition; AND
The condition must be in the accelerated phase; AND
The condition must be expressing the Philadelphia chromosome confirmed through cytogenetic analysis; or
The condition must have the transcript BCR-ABL tyrosine kinase confirmed through quantitative polymerase chain reaction (PCR); AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chronic Myeloid Leukaemia (CML)
Continuing treatment
Patient must have received initial PBS-subsidised treatment with this drug as a first-line therapy for this condition; AND
The condition must be in the blast phase; AND
The condition must be expressing the Philadelphia chromosome confirmed through cytogenetic analysis; or
The condition must have the transcript BCR-ABL tyrosine kinase confirmed through quantitative polymerase chain reaction (PCR); AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Sponsor: Dr Reddy's Laboratories (Australia) Pty Ltd ABN 16 120 092 408
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.